Tonix Pharmaceuticals’ (TNXP) “Outperform” Rating Reaffirmed at Noble Financial

Tonix Pharmaceuticals (NASDAQ:TNXP)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Noble Financial in a research report issued on Thursday,Benzinga reports. They presently have a $70.00 price objective on the stock. Noble Financial’s price objective would indicate a potential upside of 304.51% from the stock’s current price.

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a report on Monday, February 10th. They issued a “sell” rating on the stock.

Tonix Pharmaceuticals Stock Up 5.1 %

Shares of NASDAQ:TNXP traded up $0.84 during midday trading on Thursday, hitting $17.31. The stock had a trading volume of 796,135 shares, compared to its average volume of 636,641. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business’s 50-day simple moving average is $18.69 and its 200-day simple moving average is $19.75. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $1,184.00. The company has a market cap of $32.34 million, a P/E ratio of 0.00 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing the consensus estimate of ($6.23) by ($3.54). The business had revenue of $2.58 million for the quarter, compared to the consensus estimate of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, sell-side analysts forecast that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Two Sigma Investments LP acquired a new stake in Tonix Pharmaceuticals in the fourth quarter valued at $66,000. Point72 Asset Management L.P. acquired a new stake in Tonix Pharmaceuticals in the fourth quarter worth $526,000. Jane Street Group LLC increased its stake in Tonix Pharmaceuticals by 5,932.3% in the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after purchasing an additional 1,635,119 shares in the last quarter. Northern Trust Corp acquired a new position in shares of Tonix Pharmaceuticals during the fourth quarter valued at about $162,000. Finally, Geode Capital Management LLC boosted its position in Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares during the last quarter. 82.26% of the stock is currently owned by institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.